Impact of developmental pharmacology on pediatric study design: Overcoming the challenges

Journal of Allergy and Clinical Immunology

Volumn 106, Issue 3 SUPPL., 2000, Pages

  Kearns, G L ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Cytochromes; Genetic polymorphism; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CYTOCHROME; DRUG METABOLIZING ENZYME; FAMOTIDINE; LORACARBEF; MIDAZOLAM; PHENYTOIN; THEOPHYLLINE;

CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INFANT; KIDNEY CLEARANCE; NEWBORN; PEDIATRICS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0034532246     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.109419     Document Type: Article

References (37)

1. Pharmacokinetic and pharmacodynamic data collection in children and neonates: A quiet frontier
2. Challenges in providing pharmaceutical care to pediatric patients
3. Pediatric pharmacokinetics
4. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food
5. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents
6. Pharmacokinetics of pleconaril in neonates
7. Pharmacokinetics and pharmacodynamics of famotidine in children
8. Pharmacokinetics and pharmacodynamics of famotidine in infants
9. Theophylline disposition in infancy
10. Alterations in theophylline metabolism during the first year of life
11. Theophylline metabolism in human liver microsomes: Inhibition studies
12. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients
13. The effect of age, gender, and sexual maturation on the caffeine breath test
14. CYP1A2 activity in cystic fibrosis: Lack of concordance with caffeine plasma clearance
15. Pharmacogenetics in pediatrics: Implications for practice
16. Cytochrome P450 3A: Ontogeny and drug disposition
17. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence
18. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects
19. Cyclosporine pharmacokinetics in pediatric transplant recipients
20. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
21. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping
22. Expression of CYP3A in the human liver: Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
23. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
24. Population pharmacokinetics of midazolam in neonates
25. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient
26. Ibuprofen pharmacokinetics in cystic fibrosis: Association with CYP2C9 genotype
27. Caffeine acetylator phenotyping during maturation in infants
28. Higher activity of polymorphic thiopruine S-methyltransferase in erythrocytes from neonates compared to adults
29. Glucuronidation in humans: Pharmacogenetic and developmental aspects
30. Liver volume as a determinant of drug clearance in children and adolescents
31. Cytochrome P450 in normal vs adult human liver
32. Determinants of warfarin S:R ratio in orthopedic surgery patients
33. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
34. The hypoalgesic effect of tramadol in relation to CYP2D6
35. Acquisition of functional CYP2D6 activity in the first year of life
36. Developmental pharmacodynamics of cyclosporine
37. Comparative bioavailability of loracarbef chewable tablet vs oral suspension in children